JNJ - Johnson & Johnson
NYSE
->
Healthcare
->
Drug Manufacturers—General
New Brunswick,
United States
Type: Equity
JNJ price evolution
JNJ
| (in millions $) | 29 Oct 2024 | 30 Jun 2024 | 1 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3328 | $24878 | $3340 | $21859 |
| Short term investments | $597 | $745 | $1068 | |
| Net receivables | $16174 | $15794 | $14873 | $14873 |
| Inventory | $12603 | $12169 | $11181 | $11181 |
| Total current assets | $53249 | $57817 | $53495 | $53495 |
| Long term investments | ||||
| Property, plant & equipment | $20479 | $19748 | $20898 | $19898 |
| Goodwill & intangible assets | $83975 | $70902 | $70733 | |
| Total noncurrent assets | $123271 | $114964 | $114063 | |
| Total investments | $597 | $745 | $1068 | |
| Total assets | $178287 | $181088 | $167558 | $167558 |
| Current liabilities | ||||
| Accounts payable | $8954 | $8848 | $9632 | $9632 |
| Deferred revenue | ||||
| Short long term debt | $9855 | $8550 | $3451 | |
| Total current liabilities | $51759 | $53933 | $46282 | $46282 |
| Long term debt | $31289 | $31636 | $25881 | $25881 |
| Total noncurrent liabilities | $55617 | $53221 | $52502 | |
| Total debt | $41491 | $33632 | $29332 | |
| Total liabilities | $108129 | $109550 | $98784 | $98784 |
| Shareholders' equity | ||||
| Retained earnings | $155179 | $155360 | $153843 | $153843 |
| Other shareholder equity | -$12523 | -$11253 | -$12526 | -$12527 |
| Total shareholder equity | $71538 | $70020 | $68774 | |
| (in millions $) | 31 Jan 2024 | 1 Feb 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21859 | $4926 | $14487 | $13985 |
| Short term investments | $1068 | $9392 | $17121 | $11200 |
| Net receivables | $14873 | $16160 | $15283 | $13576 |
| Inventory | $11181 | $12483 | $10387 | $9344 |
| Total current assets | $53495 | $55294 | $60979 | $51237 |
| Long term investments | $2193 | |||
| Property, plant & equipment | $19898 | $20903 | $18962 | $18766 |
| Goodwill & intangible assets | $70733 | $93556 | $81638 | $89795 |
| Total noncurrent assets | $114063 | $132084 | $121039 | $123657 |
| Total investments | $1068 | $9392 | $17121 | $11200 |
| Total assets | $167558 | $187378 | $182018 | $174894 |
| Current liabilities | ||||
| Accounts payable | $9632 | $11703 | $11055 | $9505 |
| Deferred revenue | ||||
| Short long term debt | $3451 | $12771 | $3766 | $2631 |
| Total current liabilities | $46282 | $55802 | $45226 | $42493 |
| Long term debt | $25881 | $26888 | $29985 | $32635 |
| Total noncurrent liabilities | $52502 | $54772 | $62769 | $69123 |
| Total debt | $29332 | $39659 | $33751 | $35266 |
| Total liabilities | $98784 | $110574 | $107995 | $111616 |
| Shareholders' equity | ||||
| Retained earnings | $153843 | $128345 | $123060 | $113890 |
| Other shareholder equity | -$12527 | -$12940 | -$13058 | -$15242 |
| Total shareholder equity | $68774 | $76804 | $74023 | $63278 |
| (in millions $) | 29 Oct 2024 | 30 Jun 2024 | 1 Feb 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $22471 | $22447 | $21395 | |
| Cost of revenue | $6869 | |||
| Gross Profit | $15688 | $15578 | $14597 | |
| Operating activities | ||||
| Research & development | $3440 | |||
| Selling, general & administrative | $5681 | |||
| Total operating expenses | $9681 | $9302 | $9869 | |
| Operating income | $6276 | |||
| Income from continuing operations | ||||
| EBIT | $6018 | |||
| Income tax expense | $644 | $1062 | $694 | |
| Interest expense | $136 | $270 | $212 | |
| Net income | ||||
| Net income | $2694 | $4686 | $4049 | |
| Income (for common shares) | $4686 | |||
| (in millions $) | 1 Feb 2024 | 31 Dec 2022 | 2 Feb 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $85159 | $94943 | $82584 | |
| Cost of revenue | $31089 | $28427 | ||
| Gross Profit | $58606 | $63854 | $54157 | |
| Operating activities | ||||
| Research & development | $14603 | $12159 | ||
| Selling, general & administrative | $24765 | $22084 | ||
| Total operating expenses | $43231 | $40472 | $34671 | |
| Operating income | $23382 | $19486 | ||
| Income from continuing operations | ||||
| EBIT | $22001 | $16698 | ||
| Income tax expense | $1736 | $3784 | $1783 | |
| Interest expense | $489 | $276 | $201 | |
| Net income | ||||
| Net income | $35153 | $17941 | $14714 | |
| Income (for common shares) | $17941 | $14714 | ||
| (in millions $) | 29 Oct 2024 | 30 Jun 2024 | 1 Feb 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $4686 | $4049 | ||
| Operating activities | ||||
| Depreciation | $1782 | $1843 | ||
| Business acquisitions & disposals | -$12633 | -$349 | ||
| Stock-based compensation | $341 | $178 | ||
| Total cash flows from operations | $5633 | $7863 | ||
| Investing activities | ||||
| Capital expenditures | -$976 | -$1589 | ||
| Investments | $3 | $632 | ||
| Total cash flows from investing | -$17279 | -$13687 | $878 | -$1202 |
| Financing activities | ||||
| Dividends paid | -$8839 | -$2985 | -$11770 | -$2865 |
| Sale and purchase of stock | -$41 | -$29 | ||
| Net borrowings | $10626 | -$1377 | ||
| Total cash flows from financing | -$1792 | $7544 | -$15825 | -$4655 |
| Effect of exchange rate | -$91 | -$85 | -$112 | $125 |
| Change in cash and equivalents | -$1879 | -$595 | $7732 | $2131 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $35153 | $17941 | $20878 | $14714 |
| Operating activities | ||||
| Depreciation | $7486 | $6970 | $7390 | $7231 |
| Business acquisitions & disposals | -$112 | -$17109 | $651 | -$7018 |
| Stock-based compensation | $1162 | $1138 | $1135 | $1005 |
| Total cash flows from operations | $22791 | $21194 | $23410 | $23536 |
| Investing activities | ||||
| Capital expenditures | -$4543 | -$4009 | -$3652 | -$3347 |
| Investments | $5521 | $8976 | -$5174 | -$8952 |
| Total cash flows from investing | $878 | -$12371 | -$8683 | -$20825 |
| Financing activities | ||||
| Dividends paid | -$11770 | -$11682 | -$11032 | -$10481 |
| Sale and purchase of stock | -$3960 | -$4706 | -$2420 | -$2107 |
| Net borrowings | -$2953 | $7424 | -$709 | $7095 |
| Total cash flows from financing | -$15825 | -$8871 | -$14047 | -$6120 |
| Effect of exchange rate | -$112 | -$312 | -$178 | $89 |
| Change in cash and equivalents | $7732 | -$360 | $502 | -$3320 |
News
Fundamentals
| Market cap | $347.78B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.41B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -11.98% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 1.38 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.44 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.03 |
| Quick ratio | 0.79 |